Doench JG, Fusi N, Sullender M, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184-91. doi:10.1038/nbt.3437
Bandopadhayay P, Ramkissoon LA, Jain P, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016;48(3):273-82. doi:10.1038/ng.3500
Drier Y, Cotton MJ, Williamson KE, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 2016;48(3):265-72. doi:10.1038/ng.3502
Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262-9. doi:10.1038/nm.4040
Davidson SM, Papagiannakopoulos T, Olenchock BA, et al. Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. Cell Metab. 2016;23(3):517-28. doi:10.1016/j.cmet.2016.01.007
Ji Z, Song R, Huang H, Regev A, Struhl K. Transcriptome-scale RNase-footprinting of RNA-protein complexes. Nat Biotechnol. 2016;34(4):410-3. doi:10.1038/nbt.3441
Gannon HS, Kaplan N, Tsherniak A, et al. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016;14(2):207-15. doi:10.1158/1541-7786.MCR-15-0321
Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8. doi:10.1126/science.aad5214
Yu C, Mannan AM, Yvone GM, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016;34(4):419-23. doi:10.1038/nbt.3460
Goel S, Wang Q, Watt AC, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016;29(3):255-69. doi:10.1016/j.ccell.2016.02.006